Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 3 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.
Ovarian Cancer (2nd line maintenance) */PK Study
Mainland China, HK & Macau (China)
Ovarian Cancer (1st line maintenance)
IO Combo in Gastric, Ovarian, Non Small Cell Lung Cancer (NSCLC)
Glioblastoma (GBM) *- Optune
Hong Kong (China), mainland China
Gastrointestinal Stromal Tumors (GIST) (4th Line)
Other, i.e. Advanced Systemic Mastocytosis, Glioma
B-NHL - r/r FL, r/r DLBCL, r/r MCL, r/r MZL, etc.
ROS1+ advanced NSCLC, NTRK+ advanced solid tumors
Other, i.e. Triple-negative Breast Cancer (TNBC), NSCLC, HCC, etc.
Merkel cell, Anal, MSI-high Endometrial
NSCLC and other solid tumors
Gastric Cancer, Gastroesophageal Junction (GEJ)
Infectious Disease and Autoimmune
Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
Community-Acquired Bacterial Pneumonia (CABP) *
A.Baumanii Bacterial Infections